EXELIXIS

exelixis-logo

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, ... although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

#SimilarOrganizations #People #Financial #Event #Website #More

EXELIXIS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
1994-01-01

Address:
Alameda, California, United States

Country:
United States

Website Url:
http://www.exelixis.com

Total Employee:
251+

Status:
Active

Contact:
+1 6508378300

Total Funding:
379 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Google Tag Manager WordPress Font Awesome Wordpress Plugins


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

cel-sci-logo

CEL-SCI

CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.

merrimack-pharmaceuticals-logo

Merrimack Pharmaceuticals

Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.

pliant-therapeutics-logo

Pliant Therapeutics

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

eyepoint-pharmaceuticals-logo

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals specializes in the development and commercialization of ophthalmic products for the treatment of eye diseases.


Current Advisors List

stelios-papadopoulos_image

Stelios Papadopoulos Chairman of the Board of Directors @ Exelixis
Board_member
1998-01-01

george-scangos_image

George Scangos Member of Board of Directors @ Exelixis
Board_member
1996-10-01

george-poste_image

George Poste Member of the Board of Directors @ Exelixis
Board_member

Current Employees Featured

gisela-s-schwab_image

Gisela S. Schwab
Gisela S. Schwab Executive VP and Chief Medical Officer @ Exelixis
Executive VP and Chief Medical Officer

vicki-l-goodman_image

Vicki L. Goodman
Vicki L. Goodman EVP & Chief Medical Officer @ Exelixis
EVP & Chief Medical Officer
2022-01-01

stelios-papadopoulos_image

Stelios Papadopoulos
Stelios Papadopoulos Founder @ Exelixis
Founder

michael-m-morrissey_image

Michael M. Morrissey
Michael M. Morrissey President and CEO @ Exelixis
President and CEO

christopher-senner_image

Christopher Senner
Christopher Senner Executive Vice President and Chief Financial Officer @ Exelixis
Executive Vice President and Chief Financial Officer
2015-07-01

martin-schwickart_image

Martin Schwickart
Martin Schwickart Director @ Exelixis
Director
2021-01-01

Founder


corey-goodman_image

Corey Goodman

stelios-papadopoulos_image

Stelios Papadopoulos

Stock Details


Company's stock symbol is NASDAQ:EXEL

Acquisitions List

Date Company Article Price
2004-10-19 X-Ceptor Therapeutics, Inc. X-Ceptor Therapeutics, Inc. acquired by Exelixis N/A
2001-11-20 Genomica S.A.U. Genomica S.A.U. acquired by Exelixis 110 M USD
2001-04-23 TaconicArtemis GmbH TaconicArtemis GmbH acquired by Exelixis N/A
2000-09-08 Agritope Agritope acquired by Exelixis 68 M USD
1999-07-12 Metaxen LLC Metaxen LLC acquired by Exelixis N/A

Investors List

deerfield_image

Deerfield

Deerfield investment in Post-IPO Debt - Exelixis

silicon-valley-bank_image

Silicon Valley Bank

Silicon Valley Bank investment in Post-IPO Debt - Exelixis

deerfield_image

Deerfield

Deerfield investment in Post-IPO Debt - Exelixis

painewebber_image

PaineWebber

PaineWebber investment in Seed Round - Exelixis

atlas-venture_image

Atlas Venture

Atlas Venture investment in Seed Round - Exelixis

oxford-bioscience-partners_image

Oxford Bioscience Partners

Oxford Bioscience Partners investment in Seed Round - Exelixis

Official Site Inspections

http://www.exelixis.com Semrush global rank: 754.17 K Semrush visits lastest month: 53.31 K

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Exelixis" on Search Engine